Identification of novel 2-(benzo[d]isoxazol-3-yl)-2-oxo-N-phenylacetohydrazonoyl cyanide analoguesas potent EPAC antagonists

Na Ye, Yingmin Zhu, Zhiqing Liu, Fang C. Mei, Haiying Chen, Pingyuan Wang, Xiaodong Cheng, Jia Zhou

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Two series of novel EPAC antagonists are designed, synthesized and evaluated in an effort to develop diversified analogues based on the scaffold of the previously identified high-throughput (HTS) hit 1 (ESI-09). Further SAR studies reveal that the isoxazole ring A of 1 can tolerate chemical modifications with either introduction of flexible electron-donating substitutions or structurally restrictedly fusing with a phenyl ring, leading to identification of several more potent and diversified EPAC antagonists (e.g., 10 (NY0617), 14 (NY0460), 26 (NY0725), 32 (NY0561), and 33 (NY0562)) with low micromolar inhibitory activities. Molecular docking studies on compounds 10 and 33 indicate that these two series of compounds bind at a similar site with substantially different interactions with the EPAC proteins. The findings may serve as good starting points for the development of more potent EPAC antagonists as valuable pharmacological probes or potential drug candidates.

Original languageEnglish (US)
Pages (from-to)62-71
Number of pages10
JournalEuropean Journal of Medicinal Chemistry
Volume134
DOIs
StatePublished - Jul 7 2017

Fingerprint

Cyanides
Isoxazoles
Chemical modification
Scaffolds
Substitution reactions
Throughput
Pharmacology
Electrons
azastene
erythromycin propionate-N-acetylcysteinate
Pharmaceutical Preparations
Proteins

Keywords

  • Antagonist
  • EPAC
  • Exchange proteins directly activated by cAMP
  • Molecular docking

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Identification of novel 2-(benzo[d]isoxazol-3-yl)-2-oxo-N-phenylacetohydrazonoyl cyanide analoguesas potent EPAC antagonists. / Ye, Na; Zhu, Yingmin; Liu, Zhiqing; Mei, Fang C.; Chen, Haiying; Wang, Pingyuan; Cheng, Xiaodong; Zhou, Jia.

In: European Journal of Medicinal Chemistry, Vol. 134, 07.07.2017, p. 62-71.

Research output: Contribution to journalArticle

@article{b4577178885d4fa192f8b94516feead8,
title = "Identification of novel 2-(benzo[d]isoxazol-3-yl)-2-oxo-N-phenylacetohydrazonoyl cyanide analoguesas potent EPAC antagonists",
abstract = "Two series of novel EPAC antagonists are designed, synthesized and evaluated in an effort to develop diversified analogues based on the scaffold of the previously identified high-throughput (HTS) hit 1 (ESI-09). Further SAR studies reveal that the isoxazole ring A of 1 can tolerate chemical modifications with either introduction of flexible electron-donating substitutions or structurally restrictedly fusing with a phenyl ring, leading to identification of several more potent and diversified EPAC antagonists (e.g., 10 (NY0617), 14 (NY0460), 26 (NY0725), 32 (NY0561), and 33 (NY0562)) with low micromolar inhibitory activities. Molecular docking studies on compounds 10 and 33 indicate that these two series of compounds bind at a similar site with substantially different interactions with the EPAC proteins. The findings may serve as good starting points for the development of more potent EPAC antagonists as valuable pharmacological probes or potential drug candidates.",
keywords = "Antagonist, EPAC, Exchange proteins directly activated by cAMP, Molecular docking",
author = "Na Ye and Yingmin Zhu and Zhiqing Liu and Mei, {Fang C.} and Haiying Chen and Pingyuan Wang and Xiaodong Cheng and Jia Zhou",
year = "2017",
month = "7",
day = "7",
doi = "10.1016/j.ejmech.2017.04.001",
language = "English (US)",
volume = "134",
pages = "62--71",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Identification of novel 2-(benzo[d]isoxazol-3-yl)-2-oxo-N-phenylacetohydrazonoyl cyanide analoguesas potent EPAC antagonists

AU - Ye, Na

AU - Zhu, Yingmin

AU - Liu, Zhiqing

AU - Mei, Fang C.

AU - Chen, Haiying

AU - Wang, Pingyuan

AU - Cheng, Xiaodong

AU - Zhou, Jia

PY - 2017/7/7

Y1 - 2017/7/7

N2 - Two series of novel EPAC antagonists are designed, synthesized and evaluated in an effort to develop diversified analogues based on the scaffold of the previously identified high-throughput (HTS) hit 1 (ESI-09). Further SAR studies reveal that the isoxazole ring A of 1 can tolerate chemical modifications with either introduction of flexible electron-donating substitutions or structurally restrictedly fusing with a phenyl ring, leading to identification of several more potent and diversified EPAC antagonists (e.g., 10 (NY0617), 14 (NY0460), 26 (NY0725), 32 (NY0561), and 33 (NY0562)) with low micromolar inhibitory activities. Molecular docking studies on compounds 10 and 33 indicate that these two series of compounds bind at a similar site with substantially different interactions with the EPAC proteins. The findings may serve as good starting points for the development of more potent EPAC antagonists as valuable pharmacological probes or potential drug candidates.

AB - Two series of novel EPAC antagonists are designed, synthesized and evaluated in an effort to develop diversified analogues based on the scaffold of the previously identified high-throughput (HTS) hit 1 (ESI-09). Further SAR studies reveal that the isoxazole ring A of 1 can tolerate chemical modifications with either introduction of flexible electron-donating substitutions or structurally restrictedly fusing with a phenyl ring, leading to identification of several more potent and diversified EPAC antagonists (e.g., 10 (NY0617), 14 (NY0460), 26 (NY0725), 32 (NY0561), and 33 (NY0562)) with low micromolar inhibitory activities. Molecular docking studies on compounds 10 and 33 indicate that these two series of compounds bind at a similar site with substantially different interactions with the EPAC proteins. The findings may serve as good starting points for the development of more potent EPAC antagonists as valuable pharmacological probes or potential drug candidates.

KW - Antagonist

KW - EPAC

KW - Exchange proteins directly activated by cAMP

KW - Molecular docking

UR - http://www.scopus.com/inward/record.url?scp=85017126771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017126771&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2017.04.001

DO - 10.1016/j.ejmech.2017.04.001

M3 - Article

VL - 134

SP - 62

EP - 71

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -